Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus

Published:2016-08-14 Issue:3 Volume:6 Page:258-265
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Zhi Jianguo¹,Zhai Suoping¹,Boldrin Mark¹

Affiliation:

1. Roche Innovation Center New York; New York NY USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.289/fullpdf

Reference16 articles.

1. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus diabetes;Fronzo;Diabetes,2009

2. Allosteric activators of glucokinase: potential role in diabetes therapy;Grimsby;Science,2003

3. Assessing the potential of glucokinase activators in diabetes therapy;Matschinsky;Nat Rev Drug Discov,2009

4. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?;Matschinsky;Trends Pharmacol Sci,2013

5. Present status of clinical deployment of glucokinase activators;Nakamura;J Diabetes Investig,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials;Medicine;2024-02-23

2. Tetrahydropalmatine from medicinal plants activates human glucokinase to regulate glucose homeostasis;Biotechnology and Applied Biochemistry;2023-11-30

3. Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis;Frontiers in Cardiovascular Medicine;2022-11-23

4. Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study;Clinical Drug Investigation;2020-10-30

5. An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes;Current Drug Targets;2020-04-20